A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The objective of this study was to compare the efficacy of nafarelin 200 micrograms (Group A), nafarelin 400 micrograms (Group B) and the combination of nafarelin 200 micrograms and norethisterone 1.2 mg (Group C) daily, in treating symptoms of endometriosis, American Fertility Society score and adverse events during 6 months of treatment. A prospective, randomized, double-blind parallel group study was performed in two centers and 49 women with endometriosis diagnosed laparoscopically were included. The patients were seen monthly for physical examination and records were taken for bleeding pattern, symptom score and adverse events. A control laparoscopy was performed at the end of 6 months of treatment. All patients were followed 6 months after treatment. At 3 and 6 months the pelvic examination total score had decreased significantly in all three groups. The total endometriosis score was significantly reduced in Groups B and C. After 2 months the total symptom score showed a significant decrease in Groups B and C. The frequency of hot flushes during the first month of treatment was lowest in Group C, but during the rest of treatment there were no differences between the groups. Best bleeding control was obtained in Group C. We conclude that nafarelin 200 micrograms daily has as good an effect on endometriosis symptoms as nafarelin 400 micrograms daily, and the addition of norethisterone 1.2 mg results in fewer hot flushes and better bleeding control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hormone treatment of endometriosis: The estrogenthreshold hypothesis
Barbieri, R. L. (1992) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(92)91706-g · Cited by 335
MONROE, S. E., BLUMENFELD, Z., ANDERYKO, J. L., SCHRIOCK, E., HENZL, M. R., & JAFFE, R. B. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-6-1334 · Cited by 66
Cited by
ESHRE guideline: management of women with endometriosis
Dunselman, G. A. J., Vermeulen, N., Becker, C., Calhaz-Jorge, C., D'Hooghe, T., De Bie, B., Heikinheimo, O., Horne, A. W., Kiesel, L., Nap, A., et al. (2014) · Human Reproduction · doi:10.1093/humrep/det457 · Cited by 2,211
Gonadotrophin-releasing hormone analogues for pain associated with endometriosis
Veth, V. B., van de Kar, M. M., McDonnell, R., Julania, S., & Hart, R. J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008475.pub2 · Cited by 182
Bedaiwy, M. A., Allaire, C., & Alfaraj, S. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.12.024 · Cited by 126
Gonadotrophin-releasing hormone analogues for pain associated with endometriosis
Prentice, A., Deary, A., Goldbeck-Wood, S., Farquhar, C., & Smith, S. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000346 · Cited by 116
RetractedGonadotropin-releasing hormone agonist and add-back therapy: what do the data show?
Surrey, E. S. (2010) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e32833b35a7 · Cited by 64
Metadata
- Authors
- Bergqvist, A., Jacobson, J., & Harris, S.
- Venue
- Gynecological Endocrinology
- Publisher
- Informa UK Limited
- Published
- 1997-01
- Volume
- 11
- Issue
- 3
- Pages
- 187-194
- ISSN
- 0951-3590 (ISSN-L)
- 1473-0766
- OpenAlex
- W2053457125
- Cited by
- 18
- References
- 2
- FWCI
- 0.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone. https://app.cochat.ai/papers/10.3109/09513599709152533
- The paper
- Bergqvist, A., Jacobson, J., & Harris, S. (1997). A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone. Gynecological Endocrinology. https://doi.org/10.3109/09513599709152533
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.